3RD FLOOR, ALTRINCHAM, CHESHIRE, X0
Market cap: $3.2B (2/08/2026)
Price: $23.53
Amended material disclosure
Announces CEO Transition as Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
Centessa Pharmaceuticals Enters Amended Sales Agreement with Leerink
Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
Reports Financial Results and Business Highlights for the Second Quarter of 2025
Shareholder votes
Centessa Pharmaceuticals Clears IND for ORX142, Plans Clinical Data Release
Q3
Q2
Q1
FY 2024
Amended Quarterly Report
Q3 amended
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
S-1MEF
SEC Staff Correspondence